stockrow
Saturday 7 November 2026
Export AGEN’s income statement to Excel — free account
Agenus Inc.
AGEN Healthcare Biotechnology
Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024.
- Revenue
- +4.14%
- EPS
- −99.0%
- Free cash flow
- −37.1%
- Total debt
- −28.6%
Quarter to September 2026, against a year earlier
7.13
0.69
+10.71%
Follow AGEN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 2.01 | 1.16 | 14.90 |
P/S ratio |
0.82 | 1.02 | 0.95 | 4.64 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(5.62) | (3.52) | (4.05) | (30.96) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.39 | 1.17 | 1.22 | 4.55 | |
EV/EBITDA |
0.00 | 9.34 | 3.94 | 11.21 | |
EV/Operating CF |
(2.05) | (1.66) | (1.64) | (5.87) | |
EV/FCF |
(2.06) | (1.67) | (1.64) | (5.89) | |
Quick Ratio |
0.03 | 0.36 | 0.32 | 0.33 | |
Current Ratio |
0.41 | 0.38 | 0.34 | 0.73 | |
Net Debt/EBITDA |
2.78 | (0.31) | 0.96 | (3.57) | |
Debt/Assets |
19.69% | 16.19% | 17.41% | 9.95% | |
Debt/Equity |
(0.16) | (0.13) | (0.15) | (0.22) | |
Asset Turnover |
0.50 | 0.64 | 0.74 | 0.56 | |
Operating CF/Net income |
1.56 | (0.92) | 51.65 | (13.20) | |
Capex/Depreciation |
0.00 | 0.05 | 0.46 | 0.00 | |
Interest Coverage |
0.90 | 1.03 | 0.74 | 0.79 | |
Research and Development Expense of Revenue |
21.96% | 35.04% | 42.76% | 36.99% | |
Selling, General and Administrative Expense of Revenue |
35.95% | 20.33% | 24.53% | 26.78% | |
Intangible Assets out of Total Assets |
0.12 | 0.15 | 0.16 | 0.11 | |
Share Based Compensation of Revenue |
10.12% | 3.25% | 10.45% | 9.34% | |
Graham Net Nets |
(3.98) | (2.52) | (2.37) | (0.34) | |
Graham Number |
9.17 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(12.74%) | 49.70% | 86.48% | 6.71% | |
Free Cash Flow Yield |
(82.30%) | (68.76%) | (77.60%) | (16.64%) | |
Revenue per Share |
1.15 | 0.89 | 0.84 | 0.50 | |
Operating CF per Share |
(0.56) | (0.95) | (0.75) | (0.32) | |
Capex per Share |
0.00 | 0.00 | 0.01 | 0.00 | |
Free Cash Flow per Share |
(0.56) | (0.95) | (0.75) | (0.32) | |
Cash per Share |
0.10 | 0.92 | 0.45 | 1.07 | |
Shareholders Equity per Share |
(9.34) | (6.01) | (4.98) | (1.79) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(9.34) | (6.01) | (4.98) | (1.79) | |
Free Cash Flow |
(16.62) | (35.92) | (30.96) | (20.09) | |
Working Capital |
(190.05) | (153.95) | (153.01) | (55.38) | |
Capital Expenditures |
0.00 | 0.03 | 0.24 | — | |
Net Current Asset Value |
(371.22) | (319.15) | (299.73) | (209.39) | |
EV/EBIT |
0.00 | 17.75 | 4.46 | 11.69 | |
Capex to Sales |
0.00 | 0.00 | (0.01) | 0.00 | |
Price to Operating Income |
0.00 | 15.46 | 3.49 | 11.93 | |
| Other line items | |||||
Average Receivables |
3.71 | 27.21 | 27.96 | — | |
Average Payables |
72.23 | 67.66 | 66.69 | 65.99 | |
Average Assets |
226.53 | 193.33 | 178.96 | 239.72 | |
Average Common Equity |
(292.14) | (275.19) | (271.08) | (196.51) |
Columns are period end dates · fundamentals updated 5 Nov 2026